SCHEDULE: Anson Funds Discloses 7.2% Stake in Silo Pharma

Anson Funds Management LP and affiliated entities have reported a 7.2% beneficial ownership stake in Silo Pharma, Inc., totaling 952,381 shares of common stock.

Summary

• Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam collectively reported beneficial ownership of 952,381 shares of Silo Pharma, Inc. common stock.
• This represents 7.2% of Silo Pharma, Inc.'s outstanding common stock, based on 13,318,273 shares outstanding as of September 29, 2025, as reported in the Issuer's Prospectus Supplement.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Silo Pharma, Inc.
• All reporting persons share voting and dispositive power over the 952,381 shares.

Sentiment

Score: 7

Explanation: The disclosure of a significant institutional stake by Anson Funds is generally a positive signal for the company, indicating investor confidence. However, it's a passive ownership filing, not an operational update, so the sentiment is moderately positive rather than strongly so.

Positives

• Significant institutional investment by Anson Funds, potentially signaling confidence in Silo Pharma, Inc.'s prospects.
• The investment is stated to be in the ordinary course of business, not for control, suggesting a passive, potentially long-term investment.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Silo Pharma, Inc. or the reporting persons regarding future performance or strategic direction, beyond the statement that the shares were acquired in the ordinary course of business.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing indicates a significant institutional investor, Anson Funds, has taken a substantial passive stake in Silo Pharma, Inc. Such an investment can be viewed positively by the market, suggesting validation of the company's prospects, especially within the pharmaceutical or biotechnology sector where capital and institutional backing are crucial.

Comparison to Industry Standards

• This is a standard Schedule 13G filing, indicating a passive investment above the 5% threshold. Without specific financial or operational results from Silo Pharma, Inc., a direct comparison to industry-specific benchmarks or comparable companies is not applicable based solely on this ownership disclosure. The filing itself is a regulatory compliance document rather than a performance report.

Stakeholder Impact

• Shareholders: May view the institutional investment as a positive indicator of confidence, potentially leading to increased investor interest.
• Management: Could see this as validation of their strategy and potentially a stable, long-term shareholder.

Next Steps

• Anson Funds and related entities will continue to monitor their investment in Silo Pharma, Inc.
• Further Schedule 13G/D filings would be required if their ownership percentage significantly changes or if their investment intent shifts to active control.

Key Dates

Recommendation

The filing indicates a significant institutional investor has taken a passive stake in Silo Pharma, Inc. While this is generally a positive signal of confidence, the Schedule 13G itself does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It primarily confirms a substantial ownership position, suggesting a 'hold' until further fundamental information becomes available.

Keywords

Silo Pharma Inc., Anson Funds Management LP, Schedule 13G, Beneficial Ownership, Institutional Investment, Common Stock, Equity Stake, Investment Advisor